Tonix Pharmaceuticals Holding (TNXP) shares rose sharply on Monday. The stock could remain in focus over the next month as the company is scheduled to release top-line results for its lead product candidate. Positive results could provide a significant boost to TNXP shares, which have been struggling ever since the company’s product candidate episodic tension type headache failed in a proof-of-concept study.

Valeant Pharmaceuticals International (VRX) shares surged on Monday as investors welcomed the company’s decision to appoint Zoetis CFO Paul Herendeen as its new finance chief.

VRX shares have surged more than 25% in the last five trading sessions. I believe the bankruptcy fears, which were overblown in my opinion, have eased in recent weeks. I continue to believe that the value of VRX’s assets is significantly above the current market capitalization. With bankruptcy fears easing, we could see the run in VRX shares continue, especially if sentiment on IBB remains bullish.

Tokai Pharmaceuticals Tumbles In Pre-Market Trading- Tokai Pharmaceuticals (TKAI) shares have tumbled in pre-market trading today after the company disclosed that it has terminated enrollment in its Phase 2 expansion clinical trial, ARMOR2, assessing galeterone in patients with metastatic castration-resistant prostate cancer (mCRPC) who have become resistant to Medivation’s (MDVN)  Xtandi (enzalutamide). The company has also decided not to proceed with its planned study of galeterone in mCRPC patients who rapidly progress on either Xtandi or Janssen's (JNJ)  Zytiga (abiraterone acetate).

The FDA has granted its Phase 3-stage AZD3293 a Fast Track status for the treatment of early Alzheimer's disease (AD). AZD3293 inhibits an enzyme called BACE (beta secretase cleaving enzyme) which plays a key role in the formation of myelin sheaths in peripheral nerve cells.  ZD3293 is being co-developed and will be co-commercialized by Eli Lilly (LLY) and AstraZeneca (AZN).

Gilead Sciences (GILD) announced that the European Commission (EC) has approved its TRUVADA o reduce the risk of sexually acquired HIV-1 infection in uninfected adults. The approach is called pre-exposure prophylaxis.

No patents to report.

Pfizer (PFE) confirmed on Monday that it is acquiring Mediviation (MDVN) for $81.50 per share. The deal is expected to close by the fourth quarter. The offer is well above Sanofi’s offer of $52.50 per share (subsequently raised to $58.50 per share). It represents a premium of above 20% over MDVN’s closing price on Friday.

Regeneron Pharmaceuticals (REGN) has entered into an agreement with the U.S. Department of Health and Human Services' (HHS) Biomedical Advanced Research and Development Authority (BARDA) to manufacture and study two antibodies for the potential prevention and treatment of Middle East Respiratory Syndrome (MERS). There are currently no approved therapies or vaccines to prevent/treat MERS, an upper respiratory tract infection associated with a high death rate. According to the terms of the agreement, HHS will provide up to $8.9M to support packaging and labeling of the antibodies for human use, the preparation and submission of an Investigational New Drug (IND) application with the FDA and a Phase 1 study in healthy volunteers to be conducted by the National Institutes of Health.

Sophiris Bio (SPHS) has commenced a secondary offering of its shares. The company is yet to disclose the price, volume and terms of the offering.

XBiotech (XBIT) has filed for a Form S-3 with the U.S. Securities and Exchange Commission (SEC). According to the filing, the company may offer and issue from time to time up to 7,000,000 common shares in one or more transactions under the shelf prospectus. The common shares may be offered in amounts, at prices and on terms to be determined based on market conditions at the time of sale and set forth in an accompanying prospectus supplement.

No IPOs to report.

Biostar Pharmaceuticals (BSPM) reported a loss of $3.12 per share in its second quarter. The company’s revenue for the quarter was $0.62 million, down 95.6% on a year-over-year basis.

ImmunoCellular Therapeutics (IMUC) reported a loss of $0.06 per share in its second quarter, beating consensus forecast by a penny.

Company (Ticker) Brokerage Action Recommendation Price Target My Price Target
Editas Medicine (EDIT) Jefferies Group Reiterate Buy N/A N/A
Global Blood Therapeutics (GBT) Wedbush Reiterate Outperform

$66

N/A
Intercept Pharmaceuticals (ICPT) Wedbush Reiterate Outperform

$239

N/A
Idexx Laboratories (IDXX) Canaccord Genuity Reiterate Buy

$120

N/A
Illumina (ILMN) CL King Downgrade From Buy to Neutral N/A N/A
OXiGENE (OXGN) Rodman & Renhsaw Initiation Buy

$2

N/A
Medivation (MDVN) Credit Suisse Group Reiterate Outperform

$72

N/A
Medivation (MDVN) Citigroup Downgrade/Price Target Raised From Buy to Neutral From $73 to $81.50 N/A
Medivation (MDVN) SunTrust Banks Downgrade From Buy to Neutral N/A N/A
Medivation (MDVN) Wedbush Downgrade From Outperform to Neutral

$81.50

N/A
Medivation (MDVN) Barclays PLC Downgrade/Price Target Raised From Overweight to Equal Weight From $70 to $81 N/A
Medivation (MDVN) Brean Capital Downgrade From Buy to Hold N/A N/A
Pfizer (PFE) Credit Suisse Group Reiterate Outperform

$40

N/A
Perrigo (PRGO) Guggenheim Reiterate Buy

$125

N/A
Regenxbio (RGNX) Chardan Capital Reiterate Buy N/A N/A
Relypsa (RLYP) Stifel Nicolaus Downgrade From Buy to Hold

$32

N/A
Valeant Pharmaceuticals International (VRX) Deutsche Bank Reiterate Positive N/A N/A

Opko Health (OPK)- Dr. Phillip Frost, CEO & Chairman, bought 11,800 shares at $9.76. The total value of the transaction was $115,214. Dr. Frost now owns 160,019,143 shares of OPK.

Zosano Pharma (ZSAN)- Georgia Erbez, Interim CFO, bought 47,750 shares at $1.32. The total value of the transaction was $63,030. Erbez now owns 47,750 shares of ZSAN. Hayley Lewis, VP, Reg Affairs & Quality, bought 4,775 shares at $1.32. The total value of the transaction was $6,303. Lewis now owns 4,775 shares of ZSAN. Donald J. Kellerman, VP, Clinical Development & Medical Affairs, bought 15,920 shares at $1.32. The total value of the transaction was $21,014. Kellerman now owns 15,920 shares of ZSAN. John P. Walker, Director, bought 63,700 shares at $1.32. The total value of the transaction was $84,084. Walker now owns 63,700 shares of ZSAN. Konstantinos Alataris, President & CEO, bought 127,389 shares at $1.32. The total value of the transaction was $168,153. Alataris now owns 127,389 shares of ZSAN. Kleanthis G. Xanthopoulos, Director, bought 15,920 shares at $1.32. The total value of the transaction was $21,014. Xanthopoulos now owns 21,920 shares of ZSAN.

Seattle Genetics (SGEN)- Darren S. Cline, EVP, Commercial, sold 1,774 shares at $46.59. Cline still owns 40,973 shares of SGEN. Eric Dobmeier, COO, sold 5,411 shares at $46.59. Dobmeier still owns 67,525 shares of SGEN. Jonathan G. Drachman, CMO & EVP, R&D, sold 3,991 shares at $46.59. Drachman still owns 84,255 shares of SGEN. Vaughn B. Himes, EVP, Prov Svcs & Tech Ops, sold 3,991 shares at $46.59. Himes still owns 108,779 shares of SGEN. Clay B. Siegall, President & CEO, sold 23,381 shares at $46.59. Siegall still owns 532,734 shares of SGEN. Todd E. Simpson, CFO, sold 3,991 shares at $46.59. Simpson still owns 191,445 shares of SGEN.

Theravance Biopharma (TBPH)- Bradford J. Shafer, EVP, General Counsel, Secretary, sold 49,122 shares in three separate transactions. Shafer sold 7,174 shares at $28.55; 4,870 shares at $28.14; and 37,078 shares at $27.16. Shafer still owns 195,730 shares of TBPH.

No management changes and additions to report.

NYSE- Puma Biotechnology (PBYI) shares were among the major gainers on the NYSE. The stock closed 9.10% higher. Valeant Pharmaceuticals International (VRX) ended the day 8.80% higher.

NASDAQ- Medivation (MDVN) shares were among the major gainers on the NASDAQ. The stock closed 19.74% higher. Tonix Pharmaceuticals Holding (TNXP) ended the day 10.12% higher. NantKWest (NK) ended the day 9.92% higher. Voyager Therapeutics (VYGR) shares were among the major losers on the NASDAQ. The stock closed 6.85% lower. Histogenics (HSGX) ended the day 6.47% lower. Mirna Therapeutics (MIRN) ended the day 5.62% lower.

NYSEMKT- Actinium Pharmaceuticals (ATNM) shares were among the major movers on the NYSEMKT. The stock closed 2.44% higher.

OTC- Amarantus Bioscience Holdings (AMBS) shares were among the major movers on the OTC market. The stock closed 0.52% lower.

Company (Ticker) Short Interest as a % of Float % Change Days to Cover
Repligen (RGEN)

9.1%

-3.3%

16

Repros Therapeutics (RPRX)

2.6%

-11.2%

1

Retrophin (RTRX)

16.9%

-2.7%

11

Revance Therapeutics (RVNC)

24.2%

5.7%

24

Rigel Pharmaceuticals (RIGL)

2.6%

-0.9%

5

Ritter Pharmaceuticals (RTTR)

0.8%

662.6%

0

Sage Therapeutics (SAGE)

16.3%

12.7%

7

Sagent Pharmaceuticals (SGNT)

4.6%

-23.9%

2

Sarepta Therapeutics (SRPT)

38.3%

-7.7%

8

SciClone Pharmaceuticals (SCLN)

4.5%

-21.2%

4